326 related articles for article (PubMed ID: 27131639)
1. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Chang S; Zhang L; Xu S; Luo J; Lu X; Zhang Z; Xu T; Liu Y; Tu Z; Xu Y; Ren X; Geng M; Ding J; Pei D; Ding K
J Med Chem; 2012 Mar; 55(6):2711-23. PubMed ID: 22339342
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
[TBL] [Abstract][Full Text] [Related]
6. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
[TBL] [Abstract][Full Text] [Related]
7. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
8. Discovery of highly potent and selective EGFR
Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
[TBL] [Abstract][Full Text] [Related]
9. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Otani H; Yamamoto H; Takaoka M; Sakaguchi M; Soh J; Jida M; Ueno T; Kubo T; Asano H; Tsukuda K; Kiura K; Hatakeyama S; Kawahara E; Naomoto Y; Miyoshi S; Toyooka S
PLoS One; 2015; 10(6):e0129838. PubMed ID: 26090892
[TBL] [Abstract][Full Text] [Related]
10. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold.
Hu J; Han Y; Wang J; Liu Y; Zhao Y; Liu Y; Gong P
Bioorg Med Chem; 2018 May; 26(8):1810-1822. PubMed ID: 29486953
[TBL] [Abstract][Full Text] [Related]
11. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs.
Zhang H; Wang J; Shen Y; Wang HY; Duan WM; Zhao HY; Hei YY; Xin M; Cao YX; Zhang SQ
Eur J Med Chem; 2018 Mar; 148():221-237. PubMed ID: 29466773
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 6-alkenylamides substituted of 4-anilinothieno[2,3-d]pyrimidines as irreversible epidermal growth factor receptor inhibitors.
Ji X; Peng T; Zhang X; Li J; Yang W; Tong L; Qu R; Jiang H; Ding J; Xie H; Liu H
Bioorg Med Chem; 2014 Apr; 22(7):2366-78. PubMed ID: 24565969
[TBL] [Abstract][Full Text] [Related]
13. Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.
Lelais G; Epple R; Marsilje TH; Long YO; McNeill M; Chen B; Lu W; Anumolu J; Badiger S; Bursulaya B; DiDonato M; Fong R; Juarez J; Li J; Manuia M; Mason DE; Gordon P; Groessl T; Johnson K; Jia Y; Kasibhatla S; Li C; Isbell J; Spraggon G; Bender S; Michellys PY
J Med Chem; 2016 Jul; 59(14):6671-89. PubMed ID: 27433829
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.
Zhang Y; Lv H; Luo L; Xu Y; Pan Y; Wang Y; Lin H; Xiong J; Guo P; Zhang J; Li X; Ye F
Eur J Med Chem; 2018 Sep; 157():1300-1325. PubMed ID: 30195240
[TBL] [Abstract][Full Text] [Related]
15. Novel, selective acrylamide linked quinazolines for the treatment of double mutant EGFR-L858R/T790M Non-Small-Cell lung cancer (NSCLC).
Pawara R; Ahmad I; Nayak D; Wagh S; Wadkar A; Ansari A; Belamkar S; Surana S; Nath Kundu C; Patil C; Patel H
Bioorg Chem; 2021 Oct; 115():105234. PubMed ID: 34399322
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor.
Chan BK; Hanan EJ; Bowman KK; Bryan MC; Burdick D; Chan E; Chen Y; Clausen S; Dela Vega T; Dotson J; Eigenbrot C; Elliott RL; Heald RA; Jackson PS; Knight JD; La H; Lainchbury MD; Malek S; Purkey HE; Schaefer G; Schmidt S; Seward EM; Sideris S; Shao L; Wang S; Yeap SK; Yen I; Yu C; Heffron TP
J Med Chem; 2016 Oct; 59(19):9080-9093. PubMed ID: 27564586
[TBL] [Abstract][Full Text] [Related]
17. The synthesis of 4-arylamido-2-arylaminoprimidines as potent EGFR T790M/L858R inhibitors for NSCLC.
Chen L; Chi F; Wang T; Wang N; Li W; Liu K; Shu X; Ma X; Xu Y
Bioorg Med Chem; 2018 Dec; 26(23-24):6087-6095. PubMed ID: 30471829
[TBL] [Abstract][Full Text] [Related]
18. Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.
Han C; Huang Z; Zheng C; Wan L; Zhang L; Peng S; Ding K; Ji H; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4738-48. PubMed ID: 23668441
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
Cheng H; Nair SK; Murray BW; Almaden C; Bailey S; Baxi S; Behenna D; Cho-Schultz S; Dalvie D; Dinh DM; Edwards MP; Feng JL; Ferre RA; Gajiwala KS; Hemkens MD; Jackson-Fisher A; Jalaie M; Johnson TO; Kania RS; Kephart S; Lafontaine J; Lunney B; Liu KK; Liu Z; Matthews J; Nagata A; Niessen S; Ornelas MA; Orr ST; Pairish M; Planken S; Ren S; Richter D; Ryan K; Sach N; Shen H; Smeal T; Solowiej J; Sutton S; Tran K; Tseng E; Vernier W; Walls M; Wang S; Weinrich SL; Xin S; Xu H; Yin MJ; Zientek M; Zhou R; Kath JC
J Med Chem; 2016 Mar; 59(5):2005-24. PubMed ID: 26756222
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Qin X; Li Z; Yang L; Liu P; Hu L; Zeng C; Pan Z
Bioorg Med Chem; 2016 Jul; 24(13):2871-2881. PubMed ID: 27234887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
